Multicenter, phase III trials on the contraceptive efficacy, tolerability and safety of a new drospirenone-only pill.

Santiago PalaciosEnrico ColliPedro-Antonio Regidor

Published in: Acta obstetricia et gynecologica Scandinavica (2019)

This is the first report of a new drospirenone-only oral contraceptive providing clinical efficacy similar to combined oral contraceptives, with a good safety profile, and favorable cycle control.

Keyphrases

phase iii
open label
double blind
clinical trial
placebo controlled
phase ii
cross sectional
randomized controlled trial